Intuitive Surgical has added a range of new features into the latest version of its famous da Vinci line of surgical robots.
According to the company, da Vinci 5, which was US Food and Drug Administration (FDA)-cleared in 2024, has computational power up to 10,000 times the speed of da Vinci Xi, the progenitor of the current generation line, which was first released in 2014.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The latest tools added to da Vinci 5’s armoury are Force Gauge, a visual indicator displaying the force being applied at the da Vinci’s Force Feedback instrument tip, In-Console Video Replay, and Network CCM to enable software updates to be processed remotely.
Each of the respective products have received 510(k) clearance from the FDA.
According to Intuitive, which dominates the robotic surgery market, with a US and global market share of 86.5% and 76%, respectively, the new products’ development have been informed by customer feedback and are congruent with its long-term development strategy.
Intuitive’s CEO Dave Rosa explained: “The expanded computing power of da Vinci 5 offers an opportunity to continuously optimise and extend platform performance capabilities through sequential software releases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We pay careful attention to our customers’ long-term needs, and the integration of these latest features is the next step towards realising what we set out to achieve with da Vinci 5 – helping surgeons and care teams to optimise efficiencies, deliver improved patient outcomes, and ultimately lower the total cost of care.”
The overall global robotic surgical systems market is set to reach a valuation of $9.2bn by 2034, up from $2.9bn in 2024, as per a GlobalData market model. Meanwhile, artificial intelligence (AI) in healthcare is forecast to reach a $19bn valuation by 2027. With large language models (LLMS) increasingly being used at the developmental and product implementation stages by robotics company’s, the growing areas represent a huge combined value proposition.
